IL235484A0 - Glucokinase-activating preparations for the treatment of diabetes - Google Patents

Glucokinase-activating preparations for the treatment of diabetes

Info

Publication number
IL235484A0
IL235484A0 IL235484A IL23548414A IL235484A0 IL 235484 A0 IL235484 A0 IL 235484A0 IL 235484 A IL235484 A IL 235484A IL 23548414 A IL23548414 A IL 23548414A IL 235484 A0 IL235484 A0 IL 235484A0
Authority
IL
Israel
Prior art keywords
diabetes
treatment
glucokinase activator
activator compositions
compositions
Prior art date
Application number
IL235484A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vtv Therapeutics Llc
Vtvx Holdings I Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc, Vtvx Holdings I Llc filed Critical Vtv Therapeutics Llc
Publication of IL235484A0 publication Critical patent/IL235484A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL235484A 2012-05-17 2014-11-03 Glucokinase-activating preparations for the treatment of diabetes IL235484A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648110P 2012-05-17 2012-05-17
PCT/US2013/041076 WO2013173417A2 (en) 2012-05-17 2013-05-15 Glucokinase activator compositions for the treatment of diabetes

Publications (1)

Publication Number Publication Date
IL235484A0 true IL235484A0 (en) 2014-12-31

Family

ID=48576527

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235484A IL235484A0 (en) 2012-05-17 2014-11-03 Glucokinase-activating preparations for the treatment of diabetes

Country Status (16)

Country Link
US (3) US10004782B2 (esLanguage)
EP (1) EP2849776B1 (esLanguage)
JP (1) JP6234443B2 (esLanguage)
KR (2) KR102371364B1 (esLanguage)
CN (2) CN118453592A (esLanguage)
AU (2) AU2013262895A1 (esLanguage)
BR (1) BR112014028622A2 (esLanguage)
CA (1) CA2872021C (esLanguage)
EA (1) EA201492109A1 (esLanguage)
ES (1) ES2878001T3 (esLanguage)
HK (1) HK1202458A1 (esLanguage)
IL (1) IL235484A0 (esLanguage)
IN (1) IN2014DN09554A (esLanguage)
MX (1) MX360304B (esLanguage)
SG (2) SG11201406987UA (esLanguage)
WO (1) WO2013173417A2 (esLanguage)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101878252B1 (ko) 2010-05-26 2018-07-13 브이티브이 테라퓨틱스 엘엘씨 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
IN2014DN09554A (esLanguage) 2012-05-17 2015-07-17 Transtech Pharma Llc
KR102408480B1 (ko) 2018-05-30 2022-06-10 이삼구 당뇨질환의 치료용 조성물
US20210214312A1 (en) * 2018-05-31 2021-07-15 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition and formulation containing glucokinase activator and a-glucosidase inhibitor, prepraration methods therefor and uses thereof
EP4487909A3 (en) * 2018-06-12 2025-03-19 vTv Therapeutics LLC Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US11872221B2 (en) 2020-01-31 2024-01-16 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator
WO2021151251A1 (en) * 2020-01-31 2021-08-05 Hua Medicine (Shanghai) Ltd. Treating treatment-resistant diabetes with glucokinase activator
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3185834A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with hepatic impairment
WO2021243645A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
US11857536B2 (en) 2020-06-04 2024-01-02 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CN116056760A (zh) * 2020-06-08 2023-05-02 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
KR20230048502A (ko) * 2020-06-08 2023-04-11 브이티브이 테라퓨틱스 엘엘씨 ｛2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐｝-아세트산의 염 또는 공결정 및 그의 용도
CN115350268B (zh) * 2022-08-24 2025-02-11 深圳青澜生物技术有限公司 一种用于治疗糖尿病的制剂、微针及其制备工艺

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323195B (de) 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
FR2243684B1 (esLanguage) 1973-09-19 1977-01-28 Semb
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
US6660716B1 (en) * 1999-06-21 2003-12-09 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6608038B2 (en) * 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
JP4432901B2 (ja) 2003-02-26 2010-03-17 萬有製薬株式会社 ヘテロアリールカルバモイルベンゼン誘導体
KR20060052650A (ko) 2003-07-14 2006-05-19 소니 가부시끼 가이샤 정보제공방법
AU2003269484A1 (en) 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
PL1723128T3 (pl) 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
WO2005123132A2 (en) * 2004-06-17 2005-12-29 Novo Nordisk A/S Use of liver-selective glucokinase activators
US20060246141A1 (en) 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US20100028439A1 (en) 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
CN101258137A (zh) * 2005-07-08 2008-09-03 诺沃-诺迪斯克有限公司 双环烷基脲葡糖激酶活化剂
WO2007006761A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
US7582769B2 (en) * 2005-07-08 2009-09-01 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
JP4960355B2 (ja) 2005-07-14 2012-06-27 ノボ・ノルデイスク・エー／エス ウレア型グルコキナーゼ活性化剤
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US8138185B2 (en) 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
NZ589084A (en) 2008-05-16 2012-06-29 Takeda San Diego Inc Glucokinase activators
JP5731196B2 (ja) 2008-07-22 2015-06-10 株式会社クレハ 末端ハロゲン基含量が低減されたポリアリーレンスルフィドの製造方法
WO2010107610A1 (en) * 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
JP5077786B2 (ja) 2009-04-16 2012-11-21 大正製薬株式会社 併用医薬
KR101190957B1 (ko) 2009-08-25 2012-10-15 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101878252B1 (ko) * 2010-05-26 2018-07-13 브이티브이 테라퓨틱스 엘엘씨 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
EP2392575A1 (en) * 2010-06-04 2011-12-07 LEK Pharmaceuticals d.d. A novel synthetic approach to ß-aminobutyryl substituted compounds
IN2014DN09554A (esLanguage) * 2012-05-17 2015-07-17 Transtech Pharma Llc
KR20150123838A (ko) 2013-03-04 2015-11-04 브이티브이 테라퓨틱스 엘엘씨 안정한 글루코키나제 활성화제 조성물
CA2903440C (en) 2013-03-04 2021-04-13 Vtv Therapeutics Llc Solid compositions comprising a glucokinase activator and methods of making and using the same

Also Published As

Publication number Publication date
KR20210027547A (ko) 2021-03-10
MX360304B (es) 2018-10-29
IN2014DN09554A (esLanguage) 2015-07-17
AU2013262895A1 (en) 2014-11-13
ES2878001T3 (es) 2021-11-18
US10004782B2 (en) 2018-06-26
SG11201406987UA (en) 2014-12-30
KR102371364B1 (ko) 2022-03-07
AU2017203835B2 (en) 2018-11-22
JP6234443B2 (ja) 2017-11-22
EP2849776A2 (en) 2015-03-25
CN118453592A (zh) 2024-08-09
BR112014028622A2 (pt) 2017-06-27
MX2014013105A (es) 2015-04-08
EP2849776B1 (en) 2021-04-21
US20140066372A1 (en) 2014-03-06
AU2017203835A1 (en) 2017-06-22
SG10201609644UA (en) 2017-01-27
EA201492109A1 (ru) 2015-07-30
US10980861B2 (en) 2021-04-20
JP2015517525A (ja) 2015-06-22
CA2872021A1 (en) 2013-11-21
CA2872021C (en) 2022-08-16
WO2013173417A3 (en) 2014-02-20
US10588943B2 (en) 2020-03-17
HK1202458A1 (en) 2015-10-02
US20200138909A1 (en) 2020-05-07
CN104349790A (zh) 2015-02-11
US20180311314A1 (en) 2018-11-01
KR20150013838A (ko) 2015-02-05
WO2013173417A2 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
IL235484A0 (en) Glucokinase-activating preparations for the treatment of diabetes
GB2511713B (en) Compositions for the treatment of bone fragility
ZA201403795B (en) Formulations for the treatment of diabetes
LT2916860T (lt) Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
IL237275A0 (en) Compounds for the treatment of paramoxovirus viral infections
IL231836A0 (en) The vehicle for treating the siege
PL2922893T3 (pl) Kompozycje utwardzane wilgocią, sposób ich wytwarzania i ich zastosowania
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
ZA201500229B (en) Combinations of modalities for the treatment of diabetes
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
IL240735A0 (en) Stable glucokinase activator compounds
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201408065B (en) Compositions and methods for the treatment of diabetes
LT2992094T (lt) I tipo diabeto gydymo būdai ir kompozicijos
ZA201408053B (en) Compositions and methods for the treatment of metabolic syndrome
HUP1200552A2 (en) Pharmaceutical compositions for the treatment of high blood pressure
ZA201409502B (en) Composition for treatment of warts
IL232294A0 (en) Preparations for the treatment of diabetes
HK1201731B (en) Compositions for the treatment of bone fragility
SI2812351T1 (sl) Farmacevtski sestavek za zdravljenje multiple skleroze
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds